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Abstract
Background: European treatment guidelines of TaT1 urinary bladder urothelial carcinomas depend highly on stage and
WHO1973-grade but grading reproducibility is wanting. The newer WHO2004 grading system is still debated and both
systems are currently used.
Aims: To compare reproducibility and prognostic value (of stage progression) of the WHO1973 and WHO2004.
Methods: One hundred and ninety-three primary urothelial carcinomas were reviewed. Follow-up data were retrieved from
the patient records. Kappa statistics and Harrell’s C-index were used.
Results: Median follow-up was 75 months (range 1–127). 17 patients (9%) progressed, 82% of these within and 18% after 60
months. The distribution of WHO73-grades 1, 2 and 3 was 23%, 51% and 26%, interobserver agreement for each individual
grade was 66% (kappa = 0.68), while for grades 1&2 versus 3 89% (kappa = 0.68). Intraobserver reproducibility was 68–63%
for WHO73 and 88–89% for WHO73 as 1&2 vs.3. Progression free survival rates at 5 years were 95% (grade 1), 98% (grade 2)
and 82% (grade 3) and 96% and 82% for grades 1&2 versus 3 (Hazard Ratio, HR, 5.4, p = 0.003). Using WHO2004, 62% were
low grade and 38% high grade, inter-observer agreement 87% (kappa = 0.70), intraobserver reproducibility 93%, and
progression free 5-year survival rates 97% and 85% (HR 6.6, p = 0.004). Positive and negative predictive values for stage
progression within 5 years for the WHO73 (1&2 vs. 3) were 18% and 96%, and 15% and 97% for the WHO04. Using Harrell’s
C-index, none of the grading systems was prognostically superior.
Conclusion: None of the grading systems is prognostically stronger than the others. Most importantly, inter-observer
reproducibility and sensitivities for stage progression of both systems are low and need improvement for optimal
treatment.
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Introduction
Superficial (TaT1) urothelial carcinoma (UC) is the most
common urinary bladder cancer in the Western world. Approx-
imately 70% recur and 8–30% progress to a higher T-stage [1,2].
Prognosis in TaT1 UCs depends largely on lamina propria
invasion, and grade. European treatment guidelines [3] are based
on the 1973 World Health Organization (WHO73) grading
system. The WHO73 discerns three grades (1, 2, and 3) based on
the degree of anaplasia [4] (Figure 1) but intra- and inter-observer
reproducibility is wanting and efforts have been made to develop a
more reliable grading system. Following a WHO/International
Society of Urological Pathology (ISUP) consensus conference, a
new grading system was introduced in 1998 [5] and adopted in the
WHO 2004 blue book (WHO04) [6]. The WHO04 divides the
neoplasms into benign papillomas, papillary urothelial neoplasm
of low malignant potential (PUNLMP), and low and high grade
carcinomas. The WHO04 was thought to be more reproducible
than the WHO73, but several studies have shown considerable
inter-observer variability [7,8]. There have also been discussions
on the incidence of PUNLMP with rates ranging from 12–39%,
and stage progression rates between 2 and 8% [9–11], very similar
to the low grade carcinomas.
Therefore, the aims of the current study were to compare the
inter-observer reproducibility and prognostic value (on stage
progression) of the WHO73 and WHO04 in patients with TaT1
urothelial urinary bladder cancer and the clinical significance of
distinguishing PUNLMP and low grade cancers.
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Methods
Ethics statement
The study was approved by the Norwegian Regional Ethics
Committee (REK Vest, #106/09) before the start of the study.
With approval from REK Vest, informed consent was not
obtained as the tissue samples had already been removed for
diagnostic and treatment purposes.
Patients
Two hundred and forty nine consecutive cases of primary (first
diagnosis) non-muscle invasive urothelial carcinoma of the urinary
bladder were diagnosed at the Departments of Urology and
Pathology, Stavanger University Hospital (SUH) January 1, 2002
through December 31, 2006.
Tumour tissue was obtained by transurethral resection or biopsy
at the Department of Urology, SUH. All samples were originally
routinely diagnosed as primary urothelial carcinoma WHO73
grade 1–3, pTaT1, by seven different pathologists. The tumour
tissue was fixed in 4% buffered formaldehyde, dehydrated and
embedded in paraffin. Four mm thick sections stained with
haematoxylin-erythrosine-saffron were used for routine diagnos-
tics. In total fifty-six cases were excluded from this study; the
majority of these due to inadequate sample quality (Table 1).
The patients were uniformly treated according to the national
guidelines at the time of diagnosis. All patients underwent
transurethral resection (TUR) followed by a single instillation of
a cytotoxic agent (normally 40 mg Mitomycin C). High risk
patients were treated with BCG-instillations (alternatively chemo-
therapy) over 1 to 3 years. High risk patients included Ta grade 3
tumours, T1 grade 2 or 3 tumours, primary carcinoma in situ
(CIS) without evidence of urothelial carcinoma, or concurrent CIS
in several localisations. Patients who had 3 or more separate
tumours diagnosed within 18 months of follow-up or recurrences
at multiple sites at first or second follow-up following TUR also
received instillation treatment.
Grading of urothelial carcinomas
All specimens were independently reviewed according to the
WHO73 classification (grades 1 through 3) and WHO04 (low
grade or high grade) by experienced pathologists (EG, RW, OM).
Two of the pathologists (EG and OM) repeated the classification at
a later stage. The pathologists did their evaluations in separate
sessions, independently and without prior knowledge of the
original stage, grade, each other’s assessments, their own
assessments, treatment or follow-up of the patients. In case of
discrepancies, consensus was reached after discussion using a
multihead microscope.
The WHO04 low grade tumours were also reviewed with
regards to discerning low grade and PUNLMP tumours.
Patient follow-up
Follow-up data were retrieved from medical records and from
any available new specimens at the Department of Pathology,
SUH.
The follow up protocol depended on the grade and stage of the
primary tumour. Provided that follow up cystoscopies were
Figure 1. Grading of urothelial carcinomas. A. WHO73 Grade 1/WHO04 Low grade. B. WHO73 Grade 2/WHO04 Low grade. C. WHO73 Grade 2/
WHO04 High grade. D. WHO73 Grade 3/WHO04 High grade.
doi:10.1371/journal.pone.0083192.g001
Table 1. Exclusion criteria, number of excluded and included
patients.






Previous urothelial carcinoma (on review of clinical notes) 1
cT3 or cT4 (on review of clinical notes) 3
pT2 at re-TURV 2
pT2 at review 1
Clinical metastasis at time of diagnosis 2
Lost to follow-up 11
Included in study 193
doi:10.1371/journal.pone.0083192.t001
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negative, patients with Ta grade 1 tumours would undergo
cystoscopy 3 months after initial diagnosis followed by cystoscopy
after 9 months and consequently annually for 5 years. All other
patients would have cystoscopies every 3 months for the first 2
years, every 4 months the 3rd year, every 6 month the 4th and 5th
years followed by annual cystoscopies thereafter.
Recurrence was defined as the reappearance of histopatholog-
ically confirmed urothelial carcinoma in the bladder. Progression
was defined as an advance in stage, histologically proven
metastasis or death of disease.
Statistical analysis
The inter- and intra-observer reproducibility was measured by
unweighted or quadratically weighted kappa statistics as appro-
priate. Unweighted kappa statistics were used for dichotomized
variables (WHO04 and WHO73 (1&2 vs. 3)). Weighted kappa
statistics were applied for WHO73 as this classification system has
3 categories. Quadratic weight, rather than linear weight, was used
as the difference between the second and third category (grade 2
and 3) has greater clinical implications than the difference between
the first and second category (grades 1 and 2). To evaluate the
consistency of the grading systems, mean grade was calculated
[12].
For comparison between different groups of patients, log rank
test, Kaplan-Meier survival curves and the Mann Whitney U test
were used. Median ages for patients with different WHO73 or
WHO04 grade tumours were compared by Mann Whitney U
tests. Log rank tests were used to compare survival times between
the groups of patients. The reported p-values are two-sided, i.e. the
null hypothesis is that there is no difference between the groups
and the alternate hypothesis that there is a difference. As a
measure of predictive discrimination of those who did vs. those
who did not experience progression within 5 years, we present
sensitivities, specificities, and positive and negative predictive
values (PPV and NPV). Continuity corrected confidence intervals
were estimated. Positive predictive value was defined as patients
with stage progression and high grade or grade 3 tumours (true
positives) divided by the total number of true positives and patients
with high grade (or grade 3 tumours) who did not experience
progression (false positives). Conversely, negative predictive value
was defined as patients without stage progression (true negatives)
divided by the total number of true negatives and patients with low
grade (or grade 1 and 2 tumours) who did experience progression
(false negatives). Sensitivity was defined as true positives divided by
the total number of patients with progression, and specificity was
defined as true negatives divided by the total number of patients
without progression.
The time of progression was considered in survival analyses,
using Kaplan-Meier plots and univariable Cox proportional
hazards models. The proportional hazards assumption was tested
by inspection of stratified log minus log survival plots and by
introducing time-dependent covariates into the models. The
predictive ability with regard to time of progression was measured
by Somers’ D rank correlation R function rcorr.cens of the
package Hmisc, which was transformed into Harrell’s (concor-
dance) C-index by the formula C = 0.5 * (|D|+1) [13]. Confidence
intervals for the C-indices were bootstrapped percentile intervals,
using simple nonparametric bootstrapping with 2000 samples.
Finally, in order to correct for the ‘‘optimism’’ in a concordance
measure evaluated on the same data that was used to fit the
survival model, adjusted (‘‘bootstrapped’’) C-indices were estimat-
ed (R function validate.cph of the package rms, with B = 150).
Statistical analyses were performed using IBM SPSS for
Windows version 21.0 (IBM Corp, Armonk, NY, USA), Vassar-
Stats (http://vassarstats.net) and R Project for Statistical Com-
puting (http://www.R-project.org)
Results
The median age at diagnosis was 74 years (range 39 to 95). One
hundred and forty-eight patients were male (76.7%) and 45
(23.3%) female (ratio = 3.3). Median age depended on WHO73-
grade and was 65.5 years for grade 1, 74.0 years for grade 2 and
75.0 years for grade 3 tumours (Mann Whitney U tests gave
p = 0.005 for grade 1 versus 2, p = 0.22 for 2 versus 3). For
WHO04, the median age was 71.0 years for low grade and 75.5
years for high grade tumours (p = 0.006).
Median follow-up time was 75 months (range 1–127). Histo-
logically proven recurrences occurred in 111 patients (57.5%).
Stage progression at recurrence occurred in 17 patients (15.3% of
the patients with recurrence or 8.8% of all patients), 14 of these
within 36 months and 3 more than 5 years (at 61, 62 and 101
months) after the original diagnosis. We used recurrence and
progression within 5 years after the initial diagnosis as the
endpoint because of the obvious dichotomous progression pattern
(,3years versus .5 years), and also as it seemed unlikely to us that
biomarkers can predict progression after such a long interval.
The excluded patients had a median age of 75 years (range 49–
90). 71% were male, 29% female. Median follow-up time was 35
months (0–137 months). There were no differences in sex, age,
stage, initial diagnosis (grade), or occurrence of carcinoma in situ
between the excluded and the included patients. Of the excluded
patients, 36 had true non-muscle-invasive urothelial carcinomas
with adequate follow-up. Of these, 28% recurred and 14%
progressed to a higher T-stage.
Reproducibility
The distribution of consensus WHO73-grades 1, 2 and 3 was 44
(23%), 98 (51%) and 51 (26%). One hundred and nineteen
tumours (62%) were low grade and 74 (38%) were high grade
according to the WHO04. For the final consensus WHO73
grades, there was pre-discussion consensus between the reviewing
pathologists on the grade of 39 of the grade 1 tumours (88.6%), 55
of the grade 2 tumours (56.1%), and on 34 of the grade 3 tumours
(65.4%). Regarding the final consensus WHO04 grades, there was
pre-discussion agreement on 119 of the low grade (100%) and 49
of the high grade tumours (66%). On consensus diagnosis, all
WHO73 grade 1 tumours were classified as low grade. Twenty-
four (24.5%) of the grade 2 and 50 (98.0%) of the grade 3 tumours
were re-classified as high grade tumours, and one grade 3
downgraded to a low-grade tumour.
Tables 2 and 3 summarize inter- and intraobserver overall
agreement and kappa-values with 95% confidence intervals (95%
CI). The interobserver reproducibility of the WHO73, both as
three-tiered and grades 1&2 versus 3, and the WHO04 were very
similar with overlapping confidence intervals. For pathologist 1,
intraobserver reproducibility for the WHO73 (both two-tiered and
three-tiered) is very similar to the interobserver reproducibility.
For pathologist 2 there is more variation as the WHO73 (three
tiered) seems less reproducible and the WHO04 more reproduc-
ible for this observer than the interobserver reproducibility,
however wide and overlapping confidence intervals makes a
clear-cut conclusion difficult.
In our study, only one pathologist assessed both grading systems
(OM). The mean grade difference for this pathologist is 0.3 grade
points in both grading systems (table 4). For the other pathologist
who did to reviews of a grading system (EG, WHO73), the mean
grade difference was 0.4. Due to the very low number of
Grading of Urothelial Carcinoma
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PUNLMPS, direct comparison of the mean grade of the two
systems is not feasible.
Prognostic comparison
The patients’ age was a statistically significant factor for
progression, (p = 0.004), with median time to progression 8
months for patients #73 years and 24 months for patients .73
years,), but not for recurrence (p = 0.14). Gender was not
prognostically significant (recurrence: p = 0.88; stage progression:
p = 0.96).
The recurrence rates of the three WHO73 grades were 57%,
46% and 61% after 5 years. There were no significant differences
in recurrence rates of the WHO73, the WHO73 as grades 1&2
versus 3 or the WHO04 high and low grades (51% and 54%,
p = 0.25), table 5. The progression-free survival rates for grades 1,
2 and 3 were 95%, 97% and 82% at five years after the index
specimen. The progression rate of grade 3 cases differed
(p = 0.001) from grades 1 or 2, but the progression rates between
grades 1 and 2 did not (p = 0.70).
Stage progression of the WHO04 low and high grades differed
greatly (3% versus 15%, p = 0.003). Sensitivity, specificity, hazard
ratio (HR), p-values and Harrell’s C-index for stage progression-
or-not of WHO73 and WHO04 are summarized in Tables 6–7.
With very similar Harrell’s C-indices, none of the grading systems
is prognostically stronger than the others with regard to time to
stage progression. The PPV and NPV for the two classification
systems are similar with overlapping confidence intervals uphold-
ing that none of the grading systems is stronger than the other for
predicting stage progression, The specificity of the WHO73 (1&2
vs. 3) is somewhat better than the WHO04. The sensitivity of the
WHO04 seems better than for the WHO73 (1&2 vs. 3), but 95%
confidence intervals are wide and overlapping making the
conclusion ambiguous.
There were 154 pTa (80%) and 39 pT1 (20%) tumours, with 79
(51%) and 22 (56%) recurrences (p = 0.22) and 6 and 8 progression
cases respectively (4% and 20%, p,0.001, HR = 7.0, 95%
CI = 2.4–20.3). When analysing progression in the two stages
separately, for pTa tumours there were significant differences
between the grades of both the WHO73 (grades 1&2 versus 3) and
the WHO04, but more so in the WHO73 (p,0.001 versus
p = 0.015, Figure 2). There were no significant differences between
the progression rates of the different grades in pT1 tumours.
The progression free survival rates (PFSR) of WHO73 grades
1&2 (n = 142) and WHO04 low grade (n = 117) overlapped
(PSFR = 97% and 96% respectively), although the number of
grades 1&2 was much higher than the WHO04 low grades. As
expected, the WHO73 grades 3 had a worse PFSR (82%) than the
WHO04 high grades (85%).
Papillary urothelial neoplasms of low malignant potential
Three cases were classified by the reviewing pathologists as
PUNLMP, two by the first and another case by the other. When
the cases were evaluated independently by two other pathologists,
one of these three cases was classified as low grade, leaving 2 cases
as undeniable PUNLMP. The recurrence rate was 50% and none
showed stage progression. Comparison with the original WHO
grades showed that the 2 PUNLMPs had been classified by all
Table 3. Intraobserver reproducibility.
Pathologist 1 Pathologist 2
Overall agreement (95% CI) Estimated kappa (95% CI) Overall agreement (95% CI) Estimated kappa (95% CI)
WHO73 68% (61–74%) 0.69 (0.59–0.79)* 63% (56–70%) 0.61 (0.48–0.74)*
WHO73 (1&2 vs. 3) 88% (82–92%) 0.66 (0.54–0.79) 89% (83–93%) 0.68 (0.55–0.80)
WHO04 Not performed Not performed 93% (88–96%) 0.83 (0.74–0.92)
*: Quadratic weighted kappa.
CI: Confidence interval.
doi:10.1371/journal.pone.0083192.t003
Table 2. Interobserver reproducibility.
Overall agreement
(95% CI) Kappa (95% CI)
WHO73 66% (59–73%) 0.68 (0.57–0.78)*
WHO73 (1&2 vs. 3) 89% (83–93%) 0.68 (0.56–0.80)
WHO04 87% (81–91%) 0.70 (0.59–0.81)
*: Quadratic weighted kappa.
CI: Confidence interval.
doi:10.1371/journal.pone.0083192.t002
Table 4. The difference in mean grade between the
reviewers.
EG 1 EG 2 RW 1 OM 1 OM 2
WHO73 1.83 1.79 NP 2.00 1.97
WHO04 NP NP 2.33 2.31 2.31
EG: Pathologist 1, 1st review. EG2: Pathologist 1, 2nd review. RW 1: Pathologist 2
(only one review). OM: Pathologist 3, 1st review. OM2: pathologist 3, 2nd review.
NP: Not performed.
doi:10.1371/journal.pone.0083192.t004
Table 5. Recurrence free survival at 5 years.
Threshold Recurrence/patients n (%)
WHO73 Grade 1 25/44 (57)
Grade 2 45/98 (46)
Grade 3 31/51 (61)
WHO73 (1&2 vs. 3) Grades 1&2 70/142 (49)
Grade 3 31/51 (61)
WHO04 Low grade 61/119 (51)
High grade 40/74 (54)
CI: Confidence interval.
doi:10.1371/journal.pone.0083192.t005
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pathologists as WHO73 grade 1 or WHO04 low grade at review.
The 44 grade 1 cases recurred in 57% and 4% showed stage
progression, which was not statistically different from the 2
PUNLMPs (p = 0.64 and p = 0.75). Of the low grade tumours,
58% recurred and 3% showed stage progression. Recurrence and
stage progression in the PUNLMPs and the low grade tumours by
univariate survival analysis were not different (p = 0.81 and 0.79).
Discussion
The clinical course of urinary bladder cancer is strongly
heterogeneous. Tumour stage is the most important classical
clinicopathological parameter for the prognosis of urothelial
carcinoma of the urinary bladder, but the extent of invasion is
hard to determine on (superficial) biopsies alone. Additional
prognostic value is obtained by the histology of the tumour. Well
differentiated urothelial carcinoma usually grows superficially,
while poorly differentiated urothelial carcinoma more often has an
infiltrating growth pattern at the time of presentation. In 2006, the
European Organization for Research and Treatment of Cancer
(EORTC) developed a scoring system for risk of recurrence and
progression [14]. The system is based on the following factors:
tumour size, number of tumours, prior recurrence rate, histolog-
ical grade and stage, and the presence of concomitant carcinoma
Table 6. Progression free survival at 5 years.





WHO73 Grade 1 2/44 (5) 0.71 (0.12–4.23 0.010 0.70 (0.53–0.84) 0.68
Grade 2 3/98 (3) 4.34 (0.94–20.1)
Grade 3 9/51 (18)
WHO73 (1&2 vs.
3)
Grades 1&2 5/142 (4) 5.42 (1.82–16.2) 0.003 0.70 (0.56–0.83) 0.69
Grade 3 9/51 (18)
WHO04 Low grade 3/119 (3) 6.59 (1.84–23.6) 0.004 0.72 (0.60–0.82) 0.71
High grade 11/74 (15)
CI: Confidence interval. HR: Hazard ratio.
doi:10.1371/journal.pone.0083192.t006
Table 7. Sensitivities, specificities, positive and negative predictive values of 5 years progression of the WHO73 (1&2 vs. 3) and
WHO04.
Sensitivity (95% CI) Specificity (95% CI) PPV (95% CI) NPV (95% CI)
WHO73 (1&2 vs. 3) 64% (36–86%) 77% (70–82%) 18% (9–31%) 96% (92–99%)
WHO04 79% (49–94%) 65% (57–72%) 15% (8–25%) 97% (92–99%)
CI: Confidence interval. PPV: positive predictive value. NPV: Negative predictive value.
doi:10.1371/journal.pone.0083192.t007
Figure 2. Five years progression free survival, pTa. A. WHO73 Grades 1&2 versus 3. B. WHO04 Low grade versus high grade.
doi:10.1371/journal.pone.0083192.g002
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in situ. These variables are weighted and the combined score
determines risk stratification of the patients. High risk patients are
routinely treated with BCG-instillations. The EORTC risk scores
have not been calculated in our study. The clinical information
was extracted from patient records several years after the
treatment was given. For a large proportion of the patients the
tumour size or number of tumours was not recorded, hence the
risk score is impossible to calculate.
The WHO73 grading system is a well-established and accepted
system. There have however been discussions over the reproduc-
ibility of this system, and the WHO04 grading system was
designed and hoped to be universally acceptable and better
reproducible. However, several studies have shown considerable
inter-observer variability using the WHO04 as well. In our
material, the WHO73 (as grades 1&2 versus 3) and WHO04 (as
low grade versus high grade) have nearly the same interobserver
reproducibility, which was not perfect, and slightly more variation
in the intraobserver reproducibility for one of the observers as the
WHO04 is possibly better reproducible than the WHO73. The
WHO04 has many more high-grade tumours (n = 74) than the
WHO73 (grade 3, n = 51). None of the grading systems is superior
with regards to predicting recurrence or stage progression.
The current European guidelines on treatment of non-muscle-
invasive bladder carcinoma recommends reporting according to
Table 8. Comparison of the studies by Pan et al (2010), Chen et al (2012) and Mangrud et al (2013).
Pan Chen Mangrud
Period 1991–2005 1999–2009 2002–2006
Time 15 years 10 years 5 years
Patients 2191 392 249
Included 1515 348 193
Men 1307 (86%) 287 (82.5%) 148 (76.7%)
Women (%) 208 (14%) 61 (17.5%) 45 (23.3%)
Mean age 71 (23–92) N/A 71 (39–95)
Median age N/A 68 (21–92) 74 (39–95)
Reviewers 1 1 3
Grading system WHO04 WHO73/WHO04 WHO73/WHO04
Patients with complete follow-up 874 ? 193
Median follow-up, months 74 (1–215) 47 (2–124) 75 (1–127)
IVI Treatment* 592 (39%) ? 35 (18%)
PUNLMP 212 (14.0%) 40 (11.5%) 2 (1.0%)
Low grade 706 (46.6%) 223 (64.1%) 117 (61%)
High grade 597 (39.4%) 85 (24.4%) 74 (38%)
Grade 1 N/A 125 (35.9%) 44 (23%)
Grade 2 N/A 176 (50.6%) 98 (51%)
Grade 3 N/A 47 (13.5%) 51 (26%)
pTa 1006 (66.4%) 220 (63.2%) 154 (80%)
pT1 509 (33.6%) 128 (46.8%) 39 (20%)
Recurrence, total 484 (31.9%) 122 (35.1%) 111 (57.5%)
Recurrence, PUNLMP 17.9% 25.0% 50%
Recurrence, low grade 35.0% 30.0% 59%
Recurrence, high grade 34.0% 52.9% 56%
Recurrence, grade 1 N/A 15.2% 57%
Recurrence, grade 2 N/A 42.0% 46%
Recurrence, grade 3 N/A 61.7% 61%
Progression, total 222 (14.7%) 41 (11.8%) 17 (8.8%)
Progression, PUNLMP 1.9% 0.0% 0%
Progression, low grade 6.5% 6.7% 3%
Progression, high grade 28.8% 30.6% 15%
Progression, grade 1 N/A 2.4% 4.5%
Progression, grade 2 N/A 27.0% 3.1%
Progression, grade 3 N/A 38.3% 18%
Progression, definition Advanced stage, metastasis or death. pT2 or higher Advanced stage,
metastasis or death.
*IVI Treatment: Intra-vesical instillation treatment.
N/A: Not applicable.
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both grading systems as the clinical guidelines are based on the
WHO73 but the WHO04 is also used. The improvement of the
2004 classification has been disputed by several authors with the
main debate being the PUNLMP [8,15–18]. A two-tier system
differentiating only between low grade and high grade tumours
would yield better reproducibility results. The WHO04 has not
been implemented in the clinical guidelines as the predictive value
of the grading system with respect to recurrence and stage
progression is not yet fully investigated.
Table 8 summarizes the results from the largest study on
WHO04, by Pan et al [15], a recent study comparing the WHO73
and the WHO04 grading systems by Chen et al [19] and our
study. In Pan’s study a very large number of cases were evaluated,
but it does not compare the WHO73 with the WHO04.
Moreover, the WHO04 evaluations have been done by one
pathologist only. Chen et al (2012) did compare both grading
systems, but again only one pathologist did the review. We used
three independent reviewers. Statistically, none of the grading
systems was stronger than the others with regards to predicting
recurrence or progression in our study. The proportion of
WHO73 grade 3 tumours was 26% whereas there were 38%
WHO04 high grade tumours, both considerably higher than the
overall progression rate of 9%. For patients with otherwise similar
risk factors for progression (multiplicity, tumour size, progression
rate, and stage), this could lead to overtreatment if the WHO04
high grade tumours were treated similarly to the WHO73 grade 3
tumours. This could point to a slight preference for the WHO73.
In addition, Table 6 shows that there are considerable differences
between the populations from different countries. Multicentre
international studies are needed to give a better impression about
the real value of the WHO73 and WHO04; however, a more
reasonable conclusion would be that both systems have a very low
predictive value. It therefore seems better to study new molecular
quantitative biomarkers which may have stronger prognostic value
and also can be better reproducible than conventional microscopic
evaluations, as has been found for Ki67 in breast cancer [20]. In
2010, van Rhijn et al showed that using a molecular grade,
consisting of a combination of FGFR3 mutations status and
Ki67%, could predict recurrence and progression more accurately
and more reproducibly [21]. Combining the molecular grade and
the EORTC risk score could provide clinicians with an even more
precise tool for therapy decision making with regard choice of
follow-up and treatment.
The median age in our study population was somewhat higher
than reported by others [6,22], but in Norway, the median age at
diagnosis of new cancers (primary diagnosis) of the bladder,
urethra and ureters in Norway in 2005–2009 falls within the 70–
74 years bracket [23]. Although the median age might be higher
than in other publications, the population of the catchment area of
SUH does not differ from the Norwegian population as a whole.
The clinical impact of PUNLMP is not yet established. As
reproducibility is low, recurrence and progression rates should be
interpreted with caution. Recurrence rates vary from 3 to 60%
[24], including several patients who have been diagnosed with
muscle-invasive carcinoma at a later stage [25]. The follow-up of
this group is controversial. Some authors believe they should be
grouped with the low grade carcinomas, as recurrence rates and
disease-specific mortality rates do not differ significantly [18,26].
However, there are also authors who argue that patients with
PUNLMP need not be followed as closely as patients with low
grade urothelial carcinomas as some studies show low recurrence
rates for PUNLMP [17]. Others add to this by arguing that the
psychological trauma may be less if the patients are not given a
cancer-label. This view has not been validated in clinical trials.
Avoiding the cancer-label might be of importance in areas where
universal health care is not available, and a history of cancer may
be negative with regards to insurance issues [16].
PUNLMPs are very rare in our material. Other studies report
PUNLMP-rates of 12–39%. As specimens from all the patients
treated for bladder cancer in the South Rogaland region are sent
to our laboratory, ours is a population based material. Both
urothelial carcinomas and papillomas from the study period were
reviewed to ensure that no PUNLMPs were falsely labelled as
papillomas. The very low incidence therefore seems real and
representative for our region. One could hypothesise that the
scarcity of PUNLMPs could be due to the tendency of a rather
medically conservative attitude in the population of the catchment
area of our hospital as preventative screening for bladder
carcinoma is not performed, and investigation and diagnosis
depend on clinical presentation.
In conclusion, there are still challenges with respect to
reproducibility and specificity to predict stage progression. We
propose further studies of the additional value of quantitative
molecular biomarkers such as proliferation markers (Ki67, PPH3
and FGFR3) and possibly also host immune response to improve
the reproducibility and prognostic value of predicting stage
progression.
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